Greg Rhee, PhD, FACE, is Associate Professor of Medicine (Psychiatry) and Public Health (Epidemiology and Biostatistics). He is a pharmaco-epidemiologist and mental health services researcher studying access to care, quality of care, and clinical and patient-reported outcomes in patients with psychiatric and/or substance use disorders. His current research focuses on mood disorders, dementias, and suicide/suicidal behaviors as well as cannabis and opioids.

As an accredited professional statistician (PStat®) certified by the American Statistical Association, his expertise is grounded in (1) population-based observational studies using large databases; (2) systematic reviews and meta-analyses of existing studies; and (3) analyses of clinical trial data. In particular, he has extensive knowledge and experience with administrative claims data (e.g., Medicare and Medicaid), national health and healthcare survey data, and other data sources including electronic health records (e.g., Epic® database from Yale-New Haven Health), RCT data, and mortality data. He also investigates long-term comparative effectiveness and cost-effectiveness of pharmacological and non-pharmacological interventions for psychiatric and/or substance use disorders.

He has 170+ peer-reviewed research articles published in highly respected medical, psychiatric, and healthcare policy journals, such as JAMA, JAMA Psychiatry, and American Journal of Psychiatry. He has also been a successful Principal Investigator or Co-Investigator on multiple research projects funded by federal agencies, including Agency for Healthcare Research and Quality (AHRQ), Food and Drug Administration (FDA), and National Institutes of Health (NIH). He is an alumnus of the University of Chicago and Yale University.

Journal Articles